Get a free sample of Skeletal Dysplasia Drugs Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Skeletal Dysplasia Drugs Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Skeletal Dysplasia Drugs Market Size
Skeletal Dysplasia Drugs Market size was valued at around USD 3 billion in 2023 and is estimated to grow at 4.2% CAGR from 2024 to 2032. Skeletal dysplasia drugs are medications specifically developed to treat and manage skeletal dysplasia, a group of genetic disorders that affect bone and cartilage growth, leading to abnormalities in the size, shape, and density of bones. These drugs aim to alleviate symptoms, improve quality of life, and in some cases, address the underlying causes of these conditions.
The increasing geriatric population is a significant driver for the drugs market. For instance, according to the National Institutes of Health, in 2023, the world's older population (aged 65 and over) continues to grow at an unprecedented rate. As per the same report, 8.5% of people worldwide (617 million) are aged 65 and over. As people age, they are more likely to develop osteoporosis and other bone density disorders, which can exacerbate the effects of dysplasia. Older adults have naturally weaker bones, making them more susceptible to fractures and other complications associated with skeletal dysplasia.
Furthermore, increasing use of bone and joint health supplements, advancement in bone growth stimulators, increasing prevalence of skeletal dysplasia and bone disorders, government initiatives and funding, and increasing education & awareness, are the supporting factors expanding the growth of the market.
How big the skeletal dysplasia drugs industry?
Skeletal dysplasia drugs market size was USD 3 billion in 2023 and is expected to register 4.2% CAGR from 2024-2032 owing to the increasing geriatric population along with rising use of bone and joint health supplements, and advancement in bone growth stimulators worldwide.
Why is the use of skeletal dysplasia drugs for morquio A syndrome growing?
Skeletal dysplasia drugs industry from the morquio A syndrome segment and is expected to reach USD 1.3 billion by 2032 due to the introduction of enzyme replacement therapy leading to rising adoption rate of medication for the syndrome.
What is the size of the U.S. skeletal dysplasia drugs market?
The U.S. skeletal dysplasia drugs industry is expected to register 4% CAGR from 2024-2032 due to the vast network of advanced healthcare facilities equipped with the latest medical technologies and specialized departments for rare diseases, including skeletal dysplasia in the region.
Who are the key leaders in the skeletal dysplasia drugs industry?
Amgen Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi, Sarepta Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Ultragenyx Pharmaceutical Inc., and Vertex Pharmaceuticals Incorporated., are some of the major skeletal dysplasia drugs companies worldwide.